http://www.confluentsurgical.com/us_trial.htm
Product Offers Promise of Improved Postoperative Outcomes and Quality of Life for Millions of Women
Waltham, MA – June 17, 2002 – Confluent Surgical, Inc., today announced the commencement of its pivotal U.S. trial for the SprayGel Adhesion Barrier in Prevention of Pelvic Adhesions In Laparoscopic Surgery, the PREVAIL Study. Confluent Surgical believes that the SprayGel Adhesion Barrier will prevent and reduce adhesions that are associated with severe postoperative pain and other side effects, which affect millions of women annually.
The first procedure in the PREVAIL Study was performed last Friday by Michael L. Twede, MD, FACOG, and Dale A. Sundwall, MD, FACOG, Medical Directors at the Salt Lake City Women’s Center. Drs. Twede and Sundwall are considered experts in the treatment of endometriosis and adhesions and are respected as highly skilled surgeons. Dr. Twede states, "Based on the early published results, SprayGel appears to represent a breakthrough in adhesion prevention. It is unique in its ability to be applied laparascopically and remain in place as a barrier for five to seven days, the period when adhesions normally form. If the results from the initial pilot study are replicated in this pivotal study, this product would prevent or significantly reduce patient trauma and costs associated with additional surgery for adhesions."
PLEASE GO TO THE ABOVE WEBSITE TO READ THE REST OF THIS INFORMATION...